Perspective on measurable residual disease testing in acute myeloid leukemia
Roland B Walter1,2,3
1Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. rwalter@fredhutch.org.
Leukemia
|November 17, 2023
Abstract
No abstract available in PubMed .
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
14.0K
07:39Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
120
